Lurasidone for major depressive disorder with mixed features and anxiety: a post-hoc analysis of a randomized, placebo-controlled study

  title={Lurasidone for major depressive disorder with mixed features and anxiety: a post-hoc analysis of a randomized, placebo-controlled study},
  author={Joyce Tsai and Michael E. Thase and Yongcai Mao and Daisy S. Ng-Mak and Andrei Pikalov and Antony Loebel},
  journal={CNS Spectrums},
  pages={236 - 245}
Objective The aim of this post-hoc analysis was to evaluate the efficacy of lurasidone in treating patients with major depressive disorder (MDD) with mixed features who present with mild and moderate-to-severe levels of anxiety. Methods The data in this analysis were derived from a study of patients meeting the DSM–IV–TR criteria for unipolar MDD, with a Montgomery–Åsberg Depression Rating Scale (MADRS) total score ≥26, presenting with two or three protocol-defined manic symptoms, who were… 
Pharmacological Treatment of Major Depressive Episodes with Mixed Features: A Systematic Review
  • I. Shim, W. Bahk, Y. Woo, B. Yoon
  • Psychology
    Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology
  • 2018
We reviewed clinical studies investigating the pharmacological treatment of major depressive episodes (MDEs) with mixed features diagnosed according to the dimensional criteria (more than two or
Acute and Maintenance Treatment of Bipolar Depression
  • E. Erten
  • Psychology, Medicine
    Noro psikiyatri arsivi
  • 2021
In this review, acute and maintenance treatment of the depressive episodes of BD will be discussed according to the treatment algorithms.
Diagnosing and treating major depressive episodes that lie along the mood disorders spectrum: focus on depression with mixed features
Randomized, placebo-controlled trials of antidepressants, antipsychotics, and mood stabilizers—alone and in combination—in individuals with carefully defined mixed depression are needed before firm treatment guidelines can be produced.
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder
These 2018 CANMAT and ISBD Bipolar Treatment Guidelines represent the significant advances in the field since the last full edition was published in 2005, including updates to diagnosis and management as well as new research into pharmacological and psychological treatments.
Current Limitations and Candidate Potential of 5-HT7 Receptor Antagonism in Psychiatric Pharmacotherapy
To explore candidate novel applications for the treatment of several neuropsychiatric disorders, including mood disorders, schizophrenia, and other cognitive disturbance disorders, the effects of 5-HT7R antagonism on transmission and intracellular signaling systems are discussed.
Effects of Subchronic Administrations of Vortioxetine, Lurasidone, and Escitalopram on Thalamocortical Glutamatergic Transmission Associated with Serotonin 5-HT7 Receptor
Results indicate that chronic administration of vortioxetine, escitalopram, and lurasidone generate downregulation of 5-HT7R in the thalamus; however, the direct inhibition of5- HT7R associated with vortoxetine and luraidone generates more rapid downregulation than the indirect elevation of the extracellular serotonin level via serotonin transporter inhibition by escitalOPram.
Altered responsiveness of the antioxidant system in chronically stressed animals: modulation by chronic lurasidone treatment
A working antioxidant machinery takes part in acute stress response and may be differentially affected by other experiences, given the essential role of stress responsiveness in almost every life process.
Mixed states in bipolar and major depressive disorders: systematic review and quality appraisal of guidelines
This systematic review provided a critical synthesis and a comprehensive overview of guidelines on the treatment of mixed states.


Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features: A Randomized, Double-Blind, Placebo-Controlled Study.
Lurasidone was effective and well tolerated in this study involving patients with major depressive disorder associated with subthreshold hypomanic symptoms (mixed features) and significant improvement in manic symptoms, assessed by the Young Mania Rating Scale, was also observed.
Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study.
Monotherapy with lurasidone in the dosage range of 20-120 mg/day significantly reduced depressive symptoms in patients with bipolar I depression.
Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features.
Anxiety in major depression does not appear to affect response to an antidepressant, and antidepressant selection should be determined by an agent's overall risk:benefit ratio, not the presence or absence of anxiety.
Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression
High baseline levels of anxiety did not reduce overall antidepressant response but did somewhat delay the onset of response to sertraline or imipramine in patients with chronic depression and significantly improved psychosocial and quality of life measures.
Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study.
Treatment with lurasidone adjunctive to lithium or valproate significantly improved depressive symptoms and was generally well tolerated in patients with bipolar I depression.
Anxiety as a correlate of response to the acute treatment of bipolar I disorder.
The findings suggest that anxiety is a clinically meaningful correlate of poor outcome in the acute treatment of bipolar I disorder.
Prevalence and clinical correlates of irritability in major depressive disorder: a preliminary report from the Sequenced Treatment Alternatives to Relieve Depression study.
Irritability is prevalent among depressed outpatients and associated with a greater likelihood of suicide attempts, poorer functional status, and greater prevalence of vascular disease, but may not represent a distinct depressive subtype per se.